Profound Medical has closed enrollment of its multi-centre TULSA clinical trial to evaluate the safety and feasibility of the Profound Medical device in patients with localized prostate cancer. Enrolled patients will be followed for 12 months following the treatment. Toronto, Ontario Canada (PRWEB) April 11, 2014
Profound Medical Inc. today announced it has closed enrollment of its TULSA (Transurethral ULtraSound Ablation) Clinical Trial with 30 patients enrolled. The TULSA Clinical Trial is a Phase I, multi-centered study designed to evaluate the safety and feasibility of the Profound Medical device in patients with localized prostate cancer. Enrolled patients will be followed for 12 months following the treatment.
The device offers the prospect of significantly improved clinical outcomes, and a marked departure from current methods, by virtue of its ability to treat the whole gland in one session, with the potential for unprecedented accuracy and minimal side effects.
Combining the use of thermal ultrasound therapy with real-time MR Image guidance, the Profound system operates within an MRI suite, and offers clinicians and patients a precisely targeted treatment using a minimally invasive, trans-urethral approach. The Profound treatment is completed in a single session and enables the patient to return home after a short outpatient recovery period.
“The successful enrollment for this trial represents another milestone for the company. We are grateful for the support and dedication of our clinical partners as we move to the next step to commercializing this technology,” states Steven Plymale, CEO at Profound Medical.
Click here to view the full news release online.